Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
NICOTINE
Novartis Consumer Health UK Limited
2 Milligram
Lozenges
2003-06-30
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nicotinell Mint 2 mg compressed Lozenge 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each piece of lozenge contains: Active substance: 2 mg nicotine (corresponding to 6.144 mg nicotine bitartrate dihydrate). Excipient(s): aspartame (0.01 g), maltitol (0.9 g) and sodium (9.8 mg). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Compressed lozenge White, mint flavoured, round biconvex lozenge 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Relief of nicotine withdrawal symptoms, in nicotine dependency as an aid to smoking cessation. The 2 mg strength is used when severe withdrawal symptoms are experienced. Patient counselling and support normally improve the success rate. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS AND ELDERLY Users should stop smoking completely during treatment with Nicotinell lozenge. Nicotinell Mint 2 mg lozenge is intended to be used by smokers with a strong or very strong nicotine dependency and those who have previously failed to stop smoking with the aid of nicotine replacement therapy. The optimal dosage form is selected according to the following table: IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 22/02/2011_ _CRN 2095865_ _page number: 1_ If an adverse event occurs with the use of the high dose form (2 mg lozenge), use of the low dose form (1 mg lozenge) should be considered. The initial dosage should be individualised on the basis of the patients nicotine dependence. One piece of lozenge to suck when the user feels the urge to smoke. Initially, 1 lozenge should be taken every 1-2 hours. The usual dosage is 8-12 lozenges per day. The maximum daily dose is 15 loz Read the complete document